Poultry Necrotic Enteritis: Pathogenesis, Diagnosis, and Control in Broiler Flocks

Introduction

Necrotic enteritis (NE) is an acute, often fatal, enterotoxemic disease of broiler chickens caused by the overgrowth of Clostridium perfringens type A and G strains in the small intestine [1, 82]. The disease represents a significant economic burden to the global poultry industry, with estimated annual losses exceeding USD 6 billion due to mortality, reduced feed conversion, and increased condemnations at processing [2, 3]. NE is characterized by a sudden onset of severe intestinal necrosis, typically occurring in birds between 2 and 6 weeks of age [4, 3]. The pathogenesis of NE is multifactorial, requiring a predisposing event that disrupts the normal intestinal microbiota and allows for the rapid proliferation of toxigenic C. perfringens [60, 85]. This review provides a detailed examination of the etiological agents, molecular mechanisms of pathogenesis, diagnostic approaches, and current and emerging control strategies for NE in broiler flocks.

Etiology and Predisposing Factors

Clostridium perfringens as the Primary Agent

C. perfringens is a Gram-positive, spore-forming, anaerobic rod that is a ubiquitous member of the normal intestinal microbiota of healthy chickens [5, 138]. The bacterium is classified into toxinotypes (A-G) based on the production of major toxins (alpha, beta, epsilon, iota, and NetB) [1, 6]. While all C. perfringens strains carry the cpa gene encoding the alpha-toxin (a phospholipase C), the critical virulence factor for the induction of NE in broilers is the pore-forming toxin NetB (Necrotic Enteritis B-like toxin) [1, 6]. The netB gene is carried on a conjugative plasmid and is found predominantly in pathogenic type G strains [82, 138]. The presence of netB is strongly correlated with the ability to cause clinical disease [6, 138]. Additional accessory toxins, such as the beta2-toxin (CPB2) and the TpeL toxin, are also frequently associated with virulent isolates [82, 138].

Predisposing Factors and the Role of Coccidiosis

NE is rarely a primary disease; it is almost always precipitated by a disruption of the intestinal ecosystem [60, 85]. The most critical predisposing factor is concurrent infection with Eimeria spp., the causative agents of coccidiosis [7, 85]. Coccidial infection causes physical damage to the intestinal epithelium, creating a nutrient-rich environment (primarily plasma proteins and mucin) that favors the growth of C. perfringens [85, 97]. The resulting mucosal damage also facilitates the translocation of C. perfringens into the deeper layers of the gut wall [85]. Dietary factors, particularly high levels of indigestible, viscous, or non-starch polysaccharide (NSP) proteins in cereal-based diets (e.g., wheat, barley, rye), are also well-established risk factors [8, 9]. These diets increase intestinal viscosity, reduce digesta passage rate, and provide fermentable substrates for clostridial proliferation [8, 10]. The withdrawal of in-feed antibiotic growth promoters (AGPs) and ionophore anticoccidials has been associated with a global resurgence of NE [2, 7, 105].

Pathogenesis: Molecular and Cellular Mechanisms

The pathogenesis of NE proceeds through a defined sequence of events. Following the predisposing insult (e.g., coccidiosis), C. perfringens undergoes a massive expansion in the small intestine, reaching population densities of 10^7 to 10^9 CFU/g of intestinal content [5, 90]. This expansion is accompanied by a shift in the metabolic profile of the gut, with a marked elevation in butyric acid and other short-chain fatty acids in the jejunum [90].

Adhesion and Colonization

Pathogenic C. perfringens strains express a range of adhesins that facilitate attachment to the damaged intestinal epithelium. Key adhesins include the collagen adhesin (CnaA) and the fibronectin-binding protein (FimB) [11, 64]. The bacterium also utilizes type IV pili for adherence and biofilm formation [12, 77]. The ability to form biofilms on the mucosal surface is a critical survival strategy, protecting the pathogen from host immune responses and antimicrobial agents [12].

Toxin-Mediated Cytotoxicity

The hallmark of NE is the rapid and severe necrosis of the villous epithelium. This is primarily mediated by the NetB toxin, a member of the beta-barrel pore-forming toxin family [1, 6]. NetB binds to the host cell membrane, oligomerizes, and forms a lytic pore that causes osmotic lysis of enterocytes [6]. The resulting loss of epithelial integrity leads to massive protein leakage into the intestinal lumen, which further fuels clostridial growth [90]. Concurrently, the alpha-toxin (phospholipase C) contributes to membrane degradation and the activation of inflammatory cascades [1, 99]. The host response involves the activation of the NLRP3 inflammasome and the induction of pyroptosis, a pro-inflammatory form of programmed cell death [13, 99]. This inflammatory response, while intended to contain the infection, exacerbates tissue damage and contributes to the systemic clinical signs [99].

Systemic Effects and Bone Pathology

The acute phase of NE is characterized by severe systemic inflammation. The disease is not limited to the gut; it has significant extra-intestinal effects. NE has been shown to negatively impact bone growth and bone microstructure in broilers, likely due to the systemic inflammatory response and the malabsorption of critical nutrients like calcium and phosphorus [62]. This can manifest as increased lameness and leg deformities in affected flocks [62].

Clinical Signs and Gross Pathology

Clinical Presentation

NE typically presents as a peracute to acute disease. Clinical signs include a sudden spike in flock mortality (often 1-2% per day, but can be higher), depression, huddling, ruffled feathers, anorexia, and diarrhea [4, 3]. The diarrhea is often dark brown or greenish and may contain necrotic mucosal casts [4]. Affected birds are typically in the fastest-growing phase of the production cycle (3-4 weeks of age) [3].

Post-Mortem Lesions

On necropsy, the small intestine (particularly the jejunum and ileum) is the primary site of pathology. The intestinal wall is distended, friable, and often described as having a "Turkish towel" appearance due to the thickened, pseudomembranous lining of necrotic mucosa [4, 3]. The lumen is filled with a foul-smelling, brownish fluid and gas. The liver may be pale and congested, and the spleen is often enlarged [4]. A key differential is the presence of focal or diffuse necrotic lesions on the mucosal surface, which are pathognomonic for NE [4].

Diagnosis

Clinical and Pathological Diagnosis

A presumptive diagnosis of NE is often made based on the characteristic flock history (sudden mortality, coccidiosis history) and gross post-mortem lesions [4, 3]. Histopathological examination of the affected intestinal segments reveals severe coagulative necrosis of the villi, with a dense infiltration of Gram-positive rods in the necrotic debris [4, 139]. The presence of Eimeria spp. in the same sections should be assessed to confirm the predisposing role [139].

Microbiological and Molecular Diagnostics

Definitive diagnosis requires the isolation and characterization of C. perfringens from the intestinal lesions.

Culture: Anaerobic culture of intestinal scrapings or necrotic tissue on selective media (e.g., Tryptose Sulfite Cycloserine agar) is the gold standard [4, 3]. Colonies are typically black due to sulfite reduction and are confirmed by Gram staining and biochemical tests [4].

Molecular Detection: PCR-based assays are the most sensitive and specific methods for detecting C. perfringens and its virulence genes. Multiplex PCR targeting the cpa, netB, cpb2, and tpeL genes is used to differentiate toxigenic from non-pathogenic strains [6, 82, 138]. Quantitative PCR (qPCR) can be used to quantify the C. perfringens load in fecal or cecal samples, providing a non-invasive risk assessment tool [5, 80].

Genomic and Pangenomic Approaches: High-throughput sequencing (whole genome sequencing) has been applied to characterize the genomic diversity of C. perfringens isolates from NE-affected flocks [82, 138]. Pangenome analysis has revealed a high degree of genetic diversity, with the presence of a "core" genome and a "dispensable" genome that includes the netB plasmid and other virulence factors [14, 82]. This approach has been used to design multi-epitope vaccines targeting non-toxin antigens [14].

Non-Invasive Monitoring

Recent research has focused on developing non-invasive diagnostic tools for NE. Fecal biomarkers, such as acute-phase proteins (e.g., alpha-1-acid glycoprotein, haptoglobin), have been shown to be elevated in the feces of broilers undergoing NE, offering a potential tool for flock-level monitoring [15]. Similarly, the detection of C. perfringens spores in litter samples has been correlated with the risk of NE outbreaks [5].

flowchart TD
    A["Clinical Signs: Sudden Mortality, Depression, Diarrhea"] --> B{Post-Mortem Examination}
    B --> C["Intestinal Lesions: Focal Necrosis, Pseudomembrane"]
    C --> D["Histopathology: Coagulative Necrosis, Gram-Positive Rods"]
    D --> E{Microbiological Confirmation}
    E --> F["Anaerobic Culture: TSC Agar"]
    F --> G["PCR: cpa, netB, cpb2, tpeL"]
    G --> H["Genotyping: Toxinotype A/G"]
    H --> I["Definitive Diagnosis: Necrotic Enteritis"]
    I --> J["Risk Factor Assessment: Coccidiosis, Diet, Management"]

Control and Prevention

Vaccination

Vaccination is a cornerstone of NE control. Several vaccine platforms have been developed.

Subunit and Recombinant Vaccines: The NetB toxin is the primary target for subunit vaccines. Recombinant NetB protein, when administered parenterally or orally, has been shown to confer significant protection against NE [75, 91]. A quadrivalent fusion protein incorporating NetB, alpha-toxin, and other antigens has demonstrated efficacy in reducing lesion scores [16]. Multi-epitope vaccines designed using pangenome-based strategies are also in development [14, 64].

Live Vectored Vaccines: Attenuated Salmonella enterica serovar Enteritidis vectors have been engineered to express the NetB and alpha-toxin antigens, inducing a robust mucosal immune response [17, 18]. Similarly, recombinant Lactobacillus plantarum strains expressing multiple C. perfringens adhesins (FimB, CnaA, NetB, FBA) have been shown to provide effective protection when delivered orally [11]. Bacillus subtilis spore-based vaccines, displaying chimeric immunogens on their surface via sortase-mediated anchoring, represent another promising platform [56].

In Ovo and Intrapulmonary Delivery: The concept of "trained immunity" has been explored. In ovo delivery of CpG oligodeoxynucleotides, combined with intrapulmonary delivery of a live C. perfringens vaccine at hatch, has been shown to protect against E. coli septicemia later in the grow-out period [52]. This approach exploits the gut-lung axis to prime the immune system [93].

Microbiome Modulation and Probiotics

The use of probiotics, prebiotics, and postbiotics to modulate the gut microbiome is a key non-antibiotic strategy.

Probiotics: Bacillus spp. (e.g., B. subtilis, B. velezensis, B. licheniformis) are the most widely used probiotics for NE control. They produce a range of antimicrobial compounds (e.g., surfactin, bacteriocins) that directly inhibit C. perfringens [19, 20, 21, 22]. Bacillus velezensis has been shown to enhance intestinal health by reshaping the gut flora [23]. Enterococcus faecium (M74) has also demonstrated efficacy as a probiotic alternative [24].

Postbiotics: Cell-free supernatants from Lactobacillus spp. and Bacillus spp. contain bioactive metabolites (e.g., organic acids, enzymes, short-chain fatty acids) that can inhibit C. perfringens and modulate the immune response [19, 25, 92]. Postbiotics from Lactobacillus reuteri have been shown to improve growth performance and intestinal health in NE-challenged broilers [25].

Bacteriophages: Phage therapy is a targeted approach. Phage cocktails designed using cross-resistance-guided strategies have been effective in mitigating NE [26, 27]. Lysogenic phages infecting C. perfringens have also been characterized [28].

Dietary Interventions

Enzymes: The addition of exogenous enzymes (e.g., xylanase, beta-glucanase) to NSP-rich diets reduces intestinal viscosity and limits the availability of fermentable substrates for C. perfringens [8, 10]. Xylanase supplementation has been shown to modulate the microbiota and increase short-chain fatty acid production [10].

Organic Acids and Phytogenics: Coated organic acids (e.g., butyric, valeric, propionic) and their glycerides have been shown to reduce C. perfringens colonization and improve gut integrity [29, 54, 57]. Phytogenic feed additives, such as those derived from Artemisia argyi and Camellia sinensis (green tea), have demonstrated anti-inflammatory and antimicrobial properties [30, 74]. The flavonoid apigenin has been shown to ameliorate intestinal injury in NE models [31].

Minerals: Zinc supplementation, particularly in the form of zinc oxide quantum dots, has been shown to protect against C. perfringens-induced negative effects by modulating lipid metabolism and improving meat quality [32, 33, 58].

Antimicrobial Stewardship

The reduction of antimicrobial use (AMU) is a global priority. Surveillance data from Canada and other regions indicate that the use of ionophores and other in-feed antibiotics is declining, while the use of vaccines and probiotics is increasing [2, 34, 120]. The implementation of antimicrobial stewardship programs, including the use of antimicrobial susceptibility testing (AST) to guide therapy, is critical [34, 120].

Conclusion

Necrotic enteritis remains a major challenge for the global broiler industry. Its pathogenesis is a complex interplay between a predisposing factor (coccidiosis, diet), a rapid expansion of toxigenic C. perfringens, and the action of the NetB pore-forming toxin. Diagnosis relies on a combination of clinical signs, gross pathology, and molecular confirmation of the netB gene. Control has moved beyond the sole reliance on in-feed antibiotics. A multi-pronged approach, incorporating vaccination (subunit, live-vectored), microbiome modulation (probiotics, postbiotics, phages), dietary management (enzymes, organic acids), and strict biosecurity, is now the standard of care. The integration of genomic and pangenomic data into vaccine design and the use of non-invasive fecal biomarkers for flock-level monitoring represent the future of NE management.

References

[1] Chen J, Ma T, Yang S et al. [Research progress in the pathogenic mechanisms and prevention and control of Clostridium perfringens]. Sheng Wu Gong Cheng Xue Bao. 2026.

[2] Agunos A, Gow S, Reid-Smith R. Trends in Necrotic Enteritis and Coccidiosis Control Practices in Canadian Poultry Flocks, 2018-2023. Avian Dis. 2025.

[3] Kollár A, Selymes K, Tóth G et al. Development of a Clostridium Perfringens Challenge Model in Broiler Chickens to Evaluate the Effects of Feed Additives. Pathogens. 2025.

[4] Kouchey AB, Shah SA, Shafi M et al. Prevalence, molecular detection, and histopathological analysis of necrotic enteritis in chickens. Open Vet J. 2025.

[5] Kinstler SR, Lee MD, Wong EA et al. Correlation Between Avian Pathogenic Clostridium perfringens Spore Load and Occurrence of Necrotic Enteritis on Broiler Chicken Farms. Avian Dis. 2026.

[6] Ahmed DAA, Hassan AK, Ali DAA et al. Molecular detection and sequencing of the NetB toxin Gene of clostridium perfringens and evaluation of its pathogenicity in broiler chicken. Poult Sci. 2026.

[7] Estensmo EL, Granstad S, Stevens KB et al. A new era of coccidiosis control: Eimeria and Clostridium perfringens dynamics in vaccinated broiler flocks after the ionophore phase-out in Norway. Prev Vet Med. 2026.

[8] Estensmo EL, Sekse C, Steinhoff FS et al. Cecal microbiota and Clostridium perfringens in broilers fed barley-based diets: Effects of enzyme supplementation and degree of grinding. Poult Sci. 2026.

[9] Erinle TJ, de Oliveira MJK, Htoo JK et al. High indigestible dietary protein impairs growth and health status of nursery pigs with Salmonella Typhimurium more than with enterotoxigenic Escherichia coli F4 challenge. J Anim Sci. 2026.

[10] Khairunnesa M, Kumar A, Wu SB et al. Xylanase and Bacillus subtilis PB6 modulate microbiota and short-chain fatty acid profiles in broilers under necrotic enteritis-challenge. Poult Sci. 2026.

[11] Yang T, Wang T, Zhang G et al. Oral administration of recombinant Lactobacillus plantarum co expressing FimB, CnaA, NetB and FBA antigens targeting chicken dendritic cells provides effective protection against necrotizing enteritis in broilers. Poult Sci. 2026.

[12] Bhattrai S, Sun Z, Jenkins M et al. Biofilm formation by clinical Clostridium perfringens isolates and its suppression by thymol. Poult Sci. 2026.

[13] Zhou B, Cao Y, Zhang Y et al. Unveiling excessive feed-sources copper-induced ileitis in chickens: Insights into tight junction damage and ROS/NLRP3/pyroptosis axis. Comp Biochem Physiol C Toxicol Pharmacol. 2026.

[14] Greco JPG, Gonçalves CN, Conceição FR et al. A pangenome-based strategy for designing a multi-epitope vaccine against non-toxin antigens of necrotic enteritis-associated Clostridium perfringens. Braz J Microbiol. 2026.

[15] Mahmoud MA, Buiatte V, Baumrucker CR et al. Investigating Acute-Phase Proteins in Feces of Broiler Chickens Undergoing Necrotic Enteritis: A Potential Tool for Assessment and Monitoring. Avian Dis. 2026.

[16] Manohar MM, Campbell BE, Keyburn AL et al. Vaccination with a novel quadrivalent fusion protein protects chickens against necrotic enteritis lesions caused by Clostridium perfringens. Poult Sci. 2025.

[17] Li W, Li YA, Liu X et al. Oral immunization with attenuated Salmonella enterica serovar Enteritidis expressing dual-toxin antigen induces protective immunity against avian necrotic enteritis. Vaccine. 2026.

[18] Li W, Li YA, Liu X et al. Recombinant Attenuated Salmonella Enteritidis Vector Enhances the Immunogenicity of Clostridium perfringens EntB Antigen for Effective Prevention of Avian Necrotic Enteritis. Biomolecules. 2026.

[19] Dai Q, Ni J, Lu J et al. Probiotic characterization of Bacillus subtilis Strain BS-Q and its cell-free-supernatant-mediated inhibition of Clostridium perfringens. Lett Appl Microbiol. 2026.

[20] Wang Z, Zhang W, Dong Z et al. Optimization of culture conditions for enhanced antibacterial metabolite production by Bacillus velezensis TL and evaluation of its efficacy against necrotic enteritis in broilers. Poult Sci. 2026.

[21] Kumar A, Gharib-Naseri K, Khairunnesa M et al. Potentials of Bacillus subtilis-derived surfactin to improve performance, intestinal health and welfare of broilers under necrotic enteritis challenge. Poult Sci. 2026.

[22] Khairunnesa M, Kumar A, Gharib-Naseri K et al. Potential of Bacillus subtilis PB6 in corn-based diets to combat subclinical necrotic enteritis in broilers. Poult Sci. 2025.

[23] Peng M, Ma G, Shi W et al. Dietary supplementation with Bacillus velezensis enhances the intestinal health of broiler chickens challenged with necrotic enteritis via reshaping the structure and function of the intestinal flora. Poult Sci. 2026.

[24] Mostafa AEA, Ramadan R, Sittien A. Probiotic Enterococcus faecium (M74) as an alternative to antibiotics for controlling necrotic enteritis in broiler chickens. Sci Rep. 2026.

[25] Wu M, Zha Y, Xiong Y et al. Lactobacillus reuteri postbiotics improved growth performance and intestinal health of broilers with necrotic enteritis. BMC Vet Res. 2025.

[26] Ahn E, Kim J, Tobin I et al. Cross-resistance-guided phage cocktail design for effective mitigation of necrotic enteritis in poultry. Microbiol Res. 2026.

[27] Muneeb M, Khan EU, Saima et al. Effects of bacteriophage supplementation on performance, gut health and blood biochemistry in broilers challenged with necrotic enteritis. Res Vet Sci. 2025.

[28] Naseem H, Haider Z, Mannan S et al. Genomic and physiochemical characterization of two lysogenic bacteriophages, ΦCP5(17) and ΦCP17(i), infecting Clostridium perfringens. Arch Virol. 2025.

[29] Hamed RI, Nabil NM, Tawakol MM et al. The effective role of organic acids as antibiotic alternatives in controlling necrotic enteritis in broiler chickens. Poult Sci. 2026.

[30] Xue F, Chen Z, Wang J et al. Solid-state fermented Artemisia argyi residue improves immune response and intestinal integrity of broilers challenged with Clostridium perfringens. Poult Sci. 2025.

[31] Li Y, Zhao Q, Zhang Q et al. Dietary supplementation with apigenin ameliorates intestinal injury in broilers suffering from necrotic enteritis. Poult Sci. 2025.

[32] Xiao C, Pan X, Sun P et al. The effect of dietary zinc on growth performance, intestinal health and zinc metabolism of broilers under necrotic enteritis challenge. Poult Sci. 2026.

[33] Xiao C, Pan X, Sun P et al. Zinc improves meat quality by modulating lipid metabolism in necrotic enteritis challenged broilers. Poult Sci. 2025.

[34] Reedman C, Charlebois A, Hill S et al. Assessing the associations between antimicrobial use and antimicrobial susceptibility testing results in Clostridium perfringens in Canadian broiler chickens, turkeys, and layer chickens from 2018 to 2023. Anaerobe. 2026.

[35] Cagirgan OY, Korkmaz S, Diker KS. Intestinal microbiome in necrotic enteritis infection of broiler and comparison of treatment alternatives. Trop Anim Health Prod. 2026.

[36] Manjunaha V, Justice-Alucho CH, Lumpkins BS et al. Combined effect of black cumin seeds and bacteriophage in mitigating necrotic enteritis in broiler chickens. J Appl Microbiol. 2026.

[37] Khairunnesa M, Kumar A, Wu SB et al. Phytogenic feed additive mitigates necrotic enteritis-associated gut damage and performance loss in broilers. Poult Sci. 2026.

[38] Alizadeh M, Oladokun S, Fazel F et al. Modulation of gut immunity and microbiota by Bacteroides thetaiotaomicron confers dose-dependent protection against necrotic enteritis in broiler chickens. Poult Sci. 2026.

[39] Hall AN, Manuja S, Payling LM et al. Lactobacillus-vectored nanobodies improve broiler productivity under sub-clinical necrotic enteritis with associated microbiome and transcriptome changes. NPJ Biofilms Microbiomes. 2026.

[40] Bobrek K. Association between Heterakis dispar infections and concurrent diseases in reproductive geese: A retrospective necropsy study. Vet Parasitol. 2026.

[41] Cordioli B, Vereecken M, Drigo I et al. Experimental model for the reproduction of necrotic enteritis in turkeys using different Clostridium perfringens strains. Avian Pathol. 2026.

[42] Niraula A, Dalloul RA. Genetic basis of disease resistance to coccidiosis and necrotic enteritis in chickens. Poult Sci. 2026.

[43] Chen Y, Li Z, Xie H et al. Identification and evaluation of novel antigens PykA, CPE1060 and Mbp as G-type Clostridium perfringens subunit vaccines. Vet Microbiol. 2026.

[44] Hu X, Meng P, Han P et al. Targeted blockade of IL-23 receptor by engineered IgY antibody attenuates bacterial enteritis via reprogramming gut microbiota-immune axis in grass carp (Ctenopharyngodon idella). Int J Biol Macromol. 2025.

[45] Lu J, Petri RM, Foster J et al. Targeted ileal microbiome modulation by in ovo seaweed polyphenols (Fucus spiralis) as an alternative to in-feed antibiotics in broiler chickens. Poult Sci. 2025.

[46] Kumar R, Selim M, Armien AG et al. Reoviral Hepatitis in Young Turkey Poults-An Emerging Problem. Pathogens. 2025.

[47] Kaspersen HP, Estensmo EL, Slettemeås JS et al. Monensin phase-out in Norwegian turkey production decreases Bifidobacterium spp. abundance while enhancing microbial diversity. Microb Genom. 2025.

[48] Elkenany R, Elsayed M, Zakaria A et al. Epidemiology of potential source, risk attribution of Clostridium perfringens from Egyptian broiler farms and genetic diversity of multidrug resistance strains. Sci Rep. 2025.

[49] Hsueh CS, Zeller M, Hashish A et al. Investigation of Avian Reovirus Evolution and Cross-Species Transmission in Turkey Hosts by Segment-Based Temporal Analysis. Viruses. 2025.

[50] Whitmore MA, Guo J, Kim DM et al. Deoxycholic Acid Mitigates Necrotic Enteritis Through Selective Inhibition of Pathobionts and Enrichment of Specific Lactic Acid Bacteria. Pathogens. 2025.

[51] Ji W, Yang D, Zhang W et al. Alleviating Clostridium perfringens-Induced Gut Lesionsin Broiler Chickens by Orally Administered Bovine

Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.